Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Extends Offer for Orchid Cellmark

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America announced today that it has extended its tender offer for all of the outstanding shares of Orchid Cellmark until 6:00 p.m., New York City time, on June 15, 2011.

LabCorp announced its $85.4 million offer, or $2.80 per share, to acquire Orchid in April. Less Orchid Cellmark's cash and cash equivalents, and available for sale securities as of Dec. 31, 2010, the price of the deal is worth about $65.6 million.

A couple of weeks ago, LabCorp extended the offer to June 1, 6 p.m. EDT, after the US Federal Trade Commission requested additional information.

As of last night, Orchid shareholders had validly tendered, and not withdrawn, 24.7 million shares of Orchid common stock, including 199,438 shares of Orchid common stock tendered through notices of guaranteed delivery. The shares tendered represent around 82 percent of Orchid's outstanding stock.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.